The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria

Boehncke, Wolf-Henning; Ludwig, Ralf J.; Zollner, Thomas Matthias; Ochsendorf, Falk Rudiger; Kaufmann, Roland; Gibbs, B. F.

doi:10.1046/j.1365-2133.2003.05209_12.x

Scientific article

English

The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria

ContributorsBoehncke, Wolf-Henning; Ludwig, Ralf J.; Zollner, Thomas Matthias; Ochsendorf, Falk Rudiger; Kaufmann, Roland; Gibbs, B. F.

Published inBritish journal of dermatology, vol. 148, no. 3, p. 604-606

Publication date2003

Keywords

Adult
Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
Chronic Disease
Cyclooxygenase Inhibitors/*therapeutic use
Female
Histamine Release/drug effects
Humans
Lactones/*therapeutic use
Male
Middle Aged
Sulfones
Urticaria/*drug therapy

Affiliation entities

Not a UNIGE publication

Citation (ISO format)

BOEHNCKE, Wolf-Henning et al. The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. In: British journal of dermatology, 2003, vol. 148, n° 3, p. 604–606. doi: 10.1046/j.1365-2133.2003.05209_12.x

Article

Identifiers

PID : unige:29787
DOI : 10.1046/j.1365-2133.2003.05209_12.x
PMID : 12653769

Additional URL for this publicationhttp://onlinelibrary.wiley.com/store/10.1046/j.1365-2133.2003.05209_12.x/asset/j.1365-2133.2003.05209_12.x.pdf?v=1&t=hkp6z1ni&s=3edc34cd766c04b5708b46668220d3e3e8a559e2

Journal ISSN0007-0963

515views

0downloads

Creation09/20/2013 4:48:32 PM

First validation09/20/2013 4:48:32 PM

Update time03/14/2023 8:25:28 PM

Status update03/14/2023 8:25:28 PM

Last indexation10/30/2024 2:28:40 PM

Archive ouverte UNIGE

The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria

Technical informations